Actively Recruiting
A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants
Led by Latigo Biotherapeutics · Updated on 2026-01-23
204
Participants Needed
1
Research Sites
132 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally or intravenously administered LTG-001 in healthy male and female participants
CONDITIONS
Official Title
A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female participants aged 18 to 55 years, inclusive
- Healthy with no significant medical abnormalities based on medical history, physical exams, lab tests, and ECG
- Body mass index (BMI) between 18 and 32 kg/m2 inclusive
You will not qualify if you...
- Unable to take oral medications or have gastrointestinal problems affecting absorption
- Significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease
- History or current abuse of alcohol or recreational drugs
- Donated more than 500 mL of blood within 3 months before study start
- Known psychiatric disorders interfering with study cooperation
- Under legal custodianship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Clinical Research Unit
Christchurch, New Zealand
Actively Recruiting
Research Team
D
Desmond Padhi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here